The angiotensin converting enzyme (ACE) inhibitors market was valued at USD 11.7 billion in 2015, and is expected to reach USD 12.45 billion by 2024, growing at a CAGR of (0.7%) from 2015 to 2024
September, 2018 | Source: Profshare Market Research
The angiotensin converting enzyme (ACE) inhibitors market was valued at USD 11.7 billion in 2015, and is expected to reach USD 12.45 billion by 2024, growing at a CAGR of (0.7%) from 2015 to 2024.
Angiotensin II is a very potent chemical produced by the body that primarily circulates in the blood. It causes the muscles surrounding blood vessels to contract, thereby narrowing the vessels and it leads the increase in pressure within the vessels which increases in Blood pressure(hypertension).
Angiotensin II is formed from angiotensin I in the blood by the enzyme angiotensin converting enzyme (ACE). Angiotensin I in the blood is itself formed from angiotensinogen, a protein produced by the liver and released into the blood. Angiotensin converting enzyme inhibitors (ACE inhibitors) are medications that slow (inhibit) the activity of the enzyme ACE, which decreases the production of angiotensin II. As a result, blood vessels expands or dilate, and blood pressure is reduced. This lower blood pressure makes it easier for the heart to pump blood and can improve the function of a failing heart. In addition, the progression of kidney disease due to high blood pressure or diabetes is decreased.
ACE inhibitors are used for: Controlling acute and chronic high blood pressure, Treating left ventricular dysfunction and heart failure, Preventing strokes Preventing and treating kidney disease (nephropathy) in people with hypertension or diabetes ACE inhibitors also improve survival after heart attacks.
In studies, individuals with hypertension, heart failure, or prior heart attacks who were treated with an ACE inhibitor sustained longer than patients who did not take an ACE inhibitor.ACE inhibitors are an important group of drugs because they prevent early death resulting from hypertension, heart failure or heart attacks.Some individuals with hypertension do not respond sufficiently to ACE inhibitors alone. In these cases, other drugs often are used in combination with ACE inhibitors.
Geography segmentation of ACE inhibitors comprised regions such as North America, Europe, Asia Pacific, Latin America, Middle East and Africa. Each geography market is further split to provide market revenue for select countries such as the U.S., Canada, U.K. Germany, China, Japan, Brazil, and GCC countries. Largest regional market observed for ACE inhibitors market was North America. North America constitutes regional markets of U.S. and Canada, the rising prevalence of cardiovascular and kidney diseases, mounting obesity in the population and supportive reimbursement policies are the key drivers for periodical growth of ACE inhibitors market in this region.
The developed healthcare infrastructure, and high public awareness related to diagnosis, treatment and management of lifestyle diseases are the key factors assisting the growth of North America ACE inhibitors market.
The ACE inhibitors market is noticed as the most diversified and competitive market comprising large number of players. The market is dominated by several players, depending on their major competencies. The key players in this market are Abbott Laboratories, Pfizer, Inc., Novartis AG, Merck & Co., Astra Zeneca plc, Jhonson and Johnson Limited, Eli Lilly and Company, Sanofi SA, Bristol-Myers Squibb Company, Bayer AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., and others.
The market value of ACE Inhibitors in the city was estimated to be Rs.185,931,386 at market volume of 37,561,896. The anti-hypertensive market was found to comprise of 5% β-Blockers, 20% Calcium channel blockers, 24% ARB, 37% Diuretics and 13.5% ACE Inhibitors. The ACE Inhibitor market was divided into Ramipril (33%), Lisinopril (19%), Enalapril (18%), Imidapril (11%), Captopril (7%), Fosinopril (4%), Perindopril (4%), Benazepril (3%). High prescription inflow was a leading factor in availability of specific Brands in the market. According to the primary participants, the rate of prescription has remained the same over the past while the average selling price has decreased. This may be because of high competition among products.
The drugs containing the active substances of the angiotensin converting enzyme inhibitors class had significant increases in quantitative and value sales, bringing substantial revenues to pharmacies. From the quantitative aspect, the best-selling products were those containing Enalaprilum, while in terms of value, the best-selling medicines were those containing Perindoprilum. It was evidenced that spectacular sales were also achieved for products that have Lisinoprilum, respectively Captoprilum, as active substances. The largest quantities were marketed for the Captopril Terapia product and the highest earnings were recorded for the Prestarium medicine.
Connect With Us
- International : +1-917-795-8886
- Asia-Pacific :+91-8623077278
- Email: [email protected]
Market Research Industries
Why Profshare?
High Data Accuracy
Precise research methodology, numerous analysis models & up to date data resources to achive most accurate market values.
Customization as Needed
We can tailored the report as per your requirments & budget, Most of our clients prefer custom reports.
Budget Friendly Solution
We have quality market data for all types of budget & so now get best out of your market research budget.
Quality Support
Be assured of receving satisfactory analyst support to understand research report in-detail.